JP-2022514352-A5 -

Dates

Publication Date

20221228

Application Date

20191221

Description

All references, including publications, patents, patent applications, and published patent applications, are incorporated herein by reference in their entirety. This disclosure includes the following embodiments. [1] Compound of formula (A), [Case 1]The pharmaceutically acceptable salt, stereoisomer, or tautomer thereof (In the formula, R is hydrogen, C1 - C6 alkyl , C1 -C6 alkoxy , C3 - C8 cycloalkyl , 3-12 membered heterocyclyl, 5-10 membered heteroaryl, or C6 - C14 aryl , where the C1 - C6 alkyl , C1 - C6 alkoxy , C3 - C8 cycloalkyl , 3-12 membered heterocyclyl, 5-10 membered heteroaryl, and C6 - C14 aryl of R are independently optionally substituted with Rd ; R M is a C1 -C6 alkyl group that is hydrogenated or optionally substituted ; m is 0, 1, 2, 3, or 4; n is 0, 1, 2, 3, or 4; m + n is 1, 2, 3, or 4; X is -C(=O)-, -O-, -CH(OH)-, -S-, -S(=O)-, or -S(=O) ²- ; Y is [Case 2]And in the formula, The wavy line represents the bond point to the rest of the molecule. s is 1, 2, 3, or 4. R11 and R12 are , independently, hydrogen, C1 - C6 alkyl , C2 -C6 alkenyl , C2 - C6 alkynyl, C3 - C8 cycloalkyl , C4 - C8 cycloalkenyl , 3-12 membered heterocyclyl, 5-10 membered heteroaryl, C6- C14 aryl , halogen, cyano, -OR 14 , -NR 15 R 16 , -SR 14 , -NO 2 , -C=NH(OR 14 ), -C (O)R 14 , -OC(O)R 14 , -C(O) OR 14 , -C(O)NR 15 R 16 , -NR 14 C(O)R 15 , -NR 14 C(O ) OR 15 , -NR 14 C(O)NR 15 R 16 -S(O)R 14 , -S(O) 2 R 14 , -NR 14 S(O)R 15 , -NR 14 S(O) 2 R 15 , -S(O)NR 15 R 16 , -S(O) 2 NR 15 R 16 , or -P(O)(OR 15)(OR 16), where the C1 - C6 alkyl , C2 - C6 alkenyl , C2 - C6 alkynyl , C3 - C8 cycloalkyl , C4 - C8 cycloalkenyl , 3-12 membered heterocyclyl, 5-10 membered heteroaryl, and C6 -C14 aryl of R 11 and R 12 are each independently optionally substituted with one or more R L ; Each R 13 independently consists of C1 - C6 alkyl , C2 -C6 alkenyl , C2 -C6 alkynyl , C3 -C8 cycloalkyl, C4-C8 cycloalkenyl , 3-12 member heterocyclyl, 5-10 member heteroaryl, C6 - C14 aryl , -NR 15 R 16 , -NO 2 , -C=NH(OR 14 ), -C(O)R 14 , -OC(O)R 14 , -C(O)OR 14 , -C(O) NR 15 R 16 , -NR 14 C (O) R 15 , -NR 14 C(O) OR 15, -NR 14 C ( O )NR 15 R 16, -S(O) R 14 , -S ( O) 2 R 14 , -NR 14 S(O)R 15 , -NR 14 S(O) 2 R 15 , -S(O)NR 15 R 16 , -S(O) 2 NR 15 R 16 , or -P(O)(OR 15 )(OR 16 ), where the C1 - C6 alkyl , C2 - C6 alkenyl , C2 - C6 alkynyl , C3 - C8 cycloalkyl , C4 - C8 cycloalkenyl , 3-12 membered heterocyclyl, 5-10 membered heteroaryl, and C6 - C14 aryl of R 13 are each independently optionally substituted with one or more R L ; Each R 14 is independently hydrogen, C1 - C6 alkyl , C2 - C6 alkenyl, C2-C6 alkynyl , C3 - C8 cycloalkyl, C6 - C14 aryl , 5-10 membered heteroaryl, or 3-12 membered heterocyclil, and the C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C8 cycloalkyl, C6-C14 aryl, 5-10 membered heteroaryl, and 3-12 membered heterocyclil of R 14 are independently optionally substituted with halogen , -OH , oxo , cyano , or C1 - C6 alkyl which is optionally substituted with halogen , -OH , or oxo ; R15 and R16 are independently of each other and independently in each appearance, hydrogen, C1 - C6 alkyl , C2 - C6 alkenyl , C2 - C6 alkynyl , C3 -C8 cycloalkyl , C6 - C14 aryl , 5-10 membered heteroaryl, or 3-12 membered heterocyclil, and the C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C8 cycloalkyl, C6-C14 aryl, 5-10 membered heteroaryl, and 3-12 membered heterocyclil of R15 and R16 are independently optionally substituted with halogen , -OH , oxo , cyano , or C1 - C6 alkyl which is optionally substituted with halogen , -OH , or oxo . Alternatively, R15 and R16 , together with the atoms to which they are bonded, form a 3-6 membered heterocycline optionally substituted with a halogen, oxo, cyano, or C1-C6 alkyl group optionally substituted with a halogen , -OH, or oxo; R d is independently, in each occurrence, a halogen, C1 - C6 alkyl , C2 - C6 alkenyl , C2 - C6 alkynyl , C3 - C8 cycloalkyl , C6 - C14 aryl , 5-10 membered heteroaryl, 3-12 membered heterocyclyl, -OR 14 , -NR 15 R 16 , cyano, or nitro; Each R L independently consists of halogens, C1 - C6 alkyls , C1 - C6 alkoxys, C2-C6 alkenyls , C2 -C6 alkynyls , C3 - C8 cycloalkyls , C3 - C8 cycloalkenyls , C6 - C14 aryls , 5-10 membered heteroaryls, 3-12 membered heterocyclyls, -C(O)R 14, -OC(O)R 14, -C(O)OR 14 , -C ( O)NR 15 R 16 , -NR 14 C (O)R 15 , -NR 14 C(O)OR 15 , -NR 14 C (O) NR 15 R 16 , -S (O) R 14 , -S(O) 2 R 14 , -NR 14 S(O)R 15 , and -NR 14 S ( O) 2R15 , -S(O) NR15R16 , -S(O) 2NR15R16 , -P ( O)(OR15 ) ( OR16) , -NR15R16 , cyano , oxo, or nitro, where (1) the C1 - C6 alkoxy is optionally substituted with a halogen, -OH, oxo, cyano, C1-C6 alkoxy, or a C1-C6 alkyl which is optionally substituted with a halogen, -OH, or oxo , ( 2 ) the C1 - C6 alkyl is optionally substituted with a 5-10 member heteroaryl or a 3-12 member heterocyclil, where the 3-12 member heterocyclil is optionally substituted with a C1 - C6 alkyl , (3) the 5-10 member heteroaryl is optionally substituted with an oxo, (4) The C